Arkadios Wealth Advisors Raises Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Arkadios Wealth Advisors increased its stake in GSK PLC by 13.7%, owning a total of 62,026 shares valued at approximately $2.4 million as of the end of the last quarter.
• GSK reported earnings of $1.23 EPS for the last quarter, surpassing analysts' estimates of $1.12 and achieving a revenue of $10.64 billion, which was also above expectations.
• The company declared a quarterly dividend of $0.4206 per share, translating to an annual yield of 4.5%, despite a payout ratio of 79.17%.

Arkadios Wealth Advisors lifted its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 13.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 62,026 shares of the pharmaceutical company's stock after buying an additional 7,468 shares during the quarter. Arkadios Wealth Advisors' holdings in GSK were worth $2,403,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after buying an additional 472 shares during the period. Olde Wealth Management LLC purchased a new stake in shares of GSK in the first quarter worth approximately $36,000. First Pacific Financial purchased a new stake in shares of GSK in the first quarter worth approximately $45,000. CX Institutional purchased a new stake in shares of GSK in the first quarter worth approximately $46,000. Finally, HM Payson & Co. raised its holdings in shares of GSK by 79.7% in the first quarter. HM Payson & Co. now owns 1,308 shares of the pharmaceutical company's stock worth $51,000 after buying an additional 580 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK opened at $37.15 on Friday. The stock has a 50-day moving average of $38.98 and a two-hundred day moving average of $37.63. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. The stock has a market cap of $75.83 billion, a P/E ratio of 17.20, a P/E/G ratio of 1.59 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 50.68% and a net margin of 10.81%. The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same quarter in the previous year, the firm posted $0.43 EPS. The firm's revenue was up 1.3% compared to the same quarter last year. As a group, research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.5%. GSK's payout ratio is currently 79.17%.

Analyst Ratings Changes

Several research firms have commented on GSK. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Finally, BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.